A Mixture of Cervus elaphus sibiricus and Glycine max (L.) Merrill Inhibits Ovariectomy-Induced Bone Loss Via Regulation of Osteogenic Molecules in a Mouse Model
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24054876 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Dong-Cheol Baek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bioscience & Integrative Medicine, Daejeon Korean Hospital of Daejeon University, Daedukdae-ro 176 bun-gil 75, Daejeon 35235, Republic o…. Hauptthemen laut MEDLINE: Bone Diseases, Metabolic, Osteoporosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Osteoporosis is a metabolic skeletal disease characterized by lowered bone mineral density and quality, which lead to an increased risk of fracture. The aim of this study was to evaluate the anti-osteoporosis effects of a mixture (called BPX) of Cervus elaphus sibiricus and Glycine max (L.) Merrill and its underlying mechanisms using an ovariectomized (OVX) mouse model. BALB/c female mice (7 weeks old) were ovariectomized. From 12 weeks of ovariectomy, mice were administered BPX (600 mg/kg) mixed in a chow diet for 20 weeks. Changes in bone mineral density (BMD) and bone volume (BV), histological findings, osteogenic markers in serum, and bone formation-related molecules were analyzed. Ovariectomy notably decreased the BMD and BV scores, while these were significantly attenuated by BPX treatment in the whole body, femur, and tibia. These anti-osteoporosis effects of BPX were supported by the histological findings for bone microstructure from H&E staining, increased activity of alkaline phosphatase (ALP), but a lowered activity of tartrate-resistant acid phosphatase (TRAP) in the femur, along with other parameters in the serum, including TRAP, calcium (Ca), osteocalcin (OC), and ALP. These pharmacological actions of BPX were explained by the regulation of key molecules in the bone morphogenetic protein (BMP) and mitogen-activated protein kinase (MAPK) pathways. The present results provide experimental evidence for the clinical relevance and pharmaceutical potential of BPX as a candidate for anti-osteoporosis treatment, especially under postmenopausal conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Bioscience & Integrative Medicine, Daejeon Korean Hospital of Daejeon University, Daedukdae-ro 176 bun-gil 75, Daejeon 35235, Republic of Korea.
- Department of Korean Rehabilitation Medicine, Daejeon Korean Hospital of Daejeon University, Daedukdae-ro 176 bun-gil 75, Daejeon 35235, Republic of Korea.
ORCID-Profile: Dong-Cheol Baek, Seung-Ju Hwang, Jin-Seok Lee, Jing-Hua Wang, Chang-Gue Son, Eun-Jung Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Baek, D. C., Hwang, S. J., Lee, J. S., Wang, J. H., Son, C. G., & Lee, E. J. (2023). A Mixture of Cervus elaphus sibiricus and Glycine max (L.) Merrill Inhibits Ovariectomy-Induced Bone Loss Via Regulation of Osteogenic Molecules in a Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054876
Vancouver
Baek DC, Hwang SJ, Lee JS, Wang JH, Son CG, Lee EJ. A Mixture of Cervus elaphus sibiricus and Glycine max (L.) Merrill Inhibits Ovariectomy-Induced Bone Loss Via Regulation of Osteogenic Molecules in a Mouse Model. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054876
BibTeX
@article{Baek2023,
author = {Baek, Dong-Cheol and Hwang, Seung-Ju and Lee, Jin-Seok and Wang, Jing-Hua and Son, Chang-Gue and Lee, Eun-Jung},
title = {A Mixture of Cervus elaphus sibiricus and Glycine max (L.) Merrill Inhibits Ovariectomy-Induced Bone Loss Via Regulation of Osteogenic Molecules in a Mouse Model},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24054876}
}
EUVIMED